

**REMARKS**


Applicants request continued examination. Claims 1-33, 35, 45, and 46 were allowed in a Notice of Allowance mailed November 13, 2007. Claims 3, 4, 5, 7, 18, 19, and 33 are cancelled from the present application. Claim 1 was amended to recite Y is -S(O)<sub>m</sub>-. Support for the amendment to claim 1 may be found in the specification at page 3. Claim 6 has been amended to remove a redundant term in light of the amendment to claim 1. Claims 30, 31 and 32 have been amended to conform with U.S. practice. Claims 35, 45, and 46 have been amended to depend from claims 30 - 32. Support for the amendment to claims 35, 45, and 46 may be found in the specification at pages 9, and 21-22. Claims 1, 2, 6, 8 - 17, 20 - 32, 35, 45, and 46 are currently pending.

Applicants draw Examiner's attention to co-pending applications 10/560,013 and 10/569,524.

Applicants respectfully submit that the present application is in condition for allowance. An early consideration and Notice of Allowance is earnestly solicited.

The Commissioner is hereby authorized to charge any fees required or credit any overpayment to Deposit Account No. 07-1392

Respectfully submitted,



Karen L. Prus  
Attorney for Applicant  
Registration No. 39,337

Date: *February 11, 2008*  
GlaxoSmithKline  
Corporate Intellectual Property  
Five Moore Drive  
P.O. Box 13398  
Research Triangle Park, NC 27709-3398  
Phone: 919-483-2192  
Facsimile: 919-483-7988